Biotechnology company Ionis Pharmaceuticals, Inc. (Nasdaq:IONS) announced on Monday that Ionis' and AstraZeneca's WAINZUA (eplontersen) has received a positive recommendation from the European Union's Committee for Medicinal Products for Human Use (CHMP) for treating hereditary transthyretin-mediated amyloidosis with polyneuropathy (ATTRv-PN) in adults.
If approved by the European Commission, WAINZUA will be the only self-administered monthly treatment available in the EU for this condition.
The recommendation follows favourable results from the NEURO-TTRansform Phase 3 trial, where WAINZUA showed sustained improvements in TTR levels, neuropathy impairment, and quality of life. WAINZUA also demonstrated a favorable safety and tolerability profile throughout the trial. ATTRv-PN causes motor disability within five years and is often fatal within a decade without treatment. WAINZUA is designed to target RNA and reduce TTR protein production.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study